DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Eldelumab
Eldelumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Immunfarmakológia Immunfarmakológia
The Two Tontti Tudiul Lui Hi Ha Unit
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
(INN) for Biological and Biotechnological Substances
Bristol-Myers Squibb Company – Product Pipeline Review – 2014
PDF File of an Unedited Manuscript That Has Been Accepted for Publication
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
211 the Impact of Biological Interventions on Health-Related Quality of Life in Adults with Crohn's Disease
Chemokines and Chemokine Receptors As Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise Palak J
Ulcerative Colitis and Probiotics: an Overview
(INN) for Biological and Biotechnological Substances
Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need
Strategies to Obtain Diverse and Specific Human Monoclonal
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Top View
The Present and Future of Inflammatory Bowel Disease Treatments
A61K9/51 (2006.01) — with International Search Report (Art
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Inflammatory Bowel Disease: Exploring Gut Pathophysiology for Novel Therapeutic Targets
Novel Therapeutic Options for the Management of Inflammatory Bowel Disease
TNIP1/ABIN1 and Lupus Nephritis: Review
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Cowen Health Care Conference
Bristol-Myers Squibb -- Citi Presentation
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Bristol-Myers Squibb '
Evaluating the Placebo Endoscopic Response in Crohn's Disease Clinical Trials RP1621 STATISTICAL ANALYSIS PLAN Version 01 Stat
Brian G Feagan MD Professor of Medicine, Epidemiology and Biostatistics Senior Scientific Director, Robarts Clinical Trials Western University
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
The IBD Therapeutic Pipeline Is Primed to Produce
(INN) for Biological and Biotechnological Substances
Antibodies[Version 1; Peer Review: 2 Approved]
Diverse Threads in IBD Clinical Development
WO 2015/036956 Al 19 March 2015 (19.03.2015) P O P C T
CAPTURE Study 2089
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri